Enteral Feeding Formulas Market – By Product, By Stage, By Application, By End Use, Global Forecast, 2024 – 2032

Enteral Feeding Formulas Market Size

The global enteral feeding formulas market size was valued at around USD 7 billion in 2023 and is estimated to grow at 7.1% CAGR from 2024 to 2032. Enteral feeding formulas are liquid nutritional products crafted to nourish individuals unable to eat orally due to medical issues, including swallowing difficulties, gastrointestinal disorders, or specific neurological conditions. These formulas are administered via a feeding tube, directly targeting the stomach or small intestine.
 

As chronic diseases like cancer, stroke, multiple sclerosis, dementia, chronic liver disease, COPD, and diabetes become more prevalent, the demand for solutions to oral intake challenges is set to rise. The International Diabetes Federation (IDF) forecasts a surge in the adult diabetes population, from 537 million in 2021 to 643 million by 2030, and reaching 783 million by 2045.
 

Additionally, dietary management for sarcopenia—a condition in older adults marked by reduced muscle strength—often incorporates enteral foods. A December 2022 study in BioMed Central highlighted that sarcopenia affects 1-29% of older adults, with heightened prevalence in long-term care settings. The research underscored a link between malnutrition and sarcopenia, noting that malnourished individuals face a greater risk. Given this, and the swift growth of the elderly demographic alongside rising age-related medical conditions, the market is poised for significant expansion.
 

Furthermore, the global preterm birth rate, as reported by the World Health Organization (WHO), stands between 5-18% of all births, underscoring the rising demand for sip feeds tailored to newborns. Compounding this demand is the escalating issue of nutritional deficiencies—especially in infants and pregnant women—highlighting shortages in vital micronutrients, proteins, and other essential nutrients.
 

Enteral Feeding Formulas Market Trends

• Advancements in medical nutrition, particularly the development of specialized formulas for oncology and inflammatory bowel disease treatment, which was valued at USD 22.6 billion in 2023, are driving market expansion.
   
• The growing number of patients and elderly individuals requiring enteral feeding due to chronic illnesses, surgeries, and critical care is fueling market growth. According to the World Health Organization, by 2030, one in six people globally are expected to be aged 60 or older, with the population in this age group rising from 1 billion in 2020 to 1.4 billion. By 2050, the number of people aged 60 and over is projected to double to 2.1 billion. Additionally, the population aged 80 and older is expected to triple from 2020 to 2050, reaching 426 million. This demographic shift indicates a potential increase in the demand for enteral nutrition solutions.
   
• Enhancements in delivery systems, including smart feeding pumps and user-friendly packaging for enteral formulas, are improving patient compliance and caregiver convenience. These improvements are likely to contribute to better patient outcomes and increased adoption of enteral nutrition therapies.
   

Enteral Feeding Formulas Market Analysis

The market comprises standard formulas, disease-specific formulas, elemental formulas, semi-elemental formulas, and other variants. In 2023, standard formulas led the market, generating a revenue of USD 3.6 billion, primarily due to their widespread adoption across diverse patient groups and their cost-effectiveness.
 

• The ready availability and affordability of polymeric nutritional complete (standard) formulas, which cater to both hospital and home care settings, are poised to propel segment growth in the upcoming years.
   
• Moreover, physicians' strong endorsement of standard formulas for gastrostomy tube (G-tube) patients, especially for enhancing children's nutrition, bolsters the segment's expansion. The Journal of Pediatric Gastroenterology and Nutrition reports a notable rise in G-tube dependency among children, with a prevalence rate of 84 per 100,000 in 2020. This underscores the pivotal role of standard formulas in meeting the nutritional demands of pediatric G-tube users.
   
• Given these insights, the demand for standard formulas is anticipated to remain robust in the foreseeable future.
   

Based on stage, the enteral feeding formulas market is divided into adults and pediatric segments. In 2023, adults accounted for a dominant 82.2% share of the market revenue.
 

• The aging global population is a significant driver of this market, as older adults frequently require enteral nutrition due to health challenges. The World Health Organization (WHO) projects that from 2015 to 2050, the percentage of the global population aged over 60 will rise from 12% to 22%. Enteral feeding formulas cater to patients who can't meet their nutritional needs orally. As healthcare systems evolve to address the nutritional demands of an aging populace, this demographic shift is poised to bolster segment growth in the coming years.
   
• Chronic diseases prevalent among adults, including cancer and neurological disorders, often disrupt normal eating patterns, fueling the demand for enteral feeding formulas. The National Cancer Institute highlights an annual incidence rate of 440.5 new cancer cases per 100,000 individuals, covering both genders.
   
• Given that many cancer patients face oral feeding challenges, the reliance on alternative nutritional methods is rising. This trend in disease prevalence is anticipated to continue, driving the enteral feeding formula market as healthcare providers seek effective nutritional solutions for chronic condition patients.
   
• Consequently, these factors are set to significantly propel the segment's growth in the forecast period.
   

The enteral feeding formulas market is segmented into oncology, gastrointestinal diseases, neurological disorders, diabetes, critical care, and other applications based on application. The oncology segment is projected to reach USD 3.9 billion by 2032.
 

• The global surge in cancer cases is a primary driver for the demand for enteral feeding formulas. WHO estimates that by 2050, new cancer diagnoses will exceed 35 million, marking a 77% rise from the 20 million cases in 2022. This surge accentuates the escalating need for nutritional support, especially enteral feeding, among cancer patients.
   
• Due to treatment side effects, oncology patients often struggle with oral intake. Side effects from chemotherapy and radiation, such as nausea and mouth sores, make enteral feeding formulas a viable solution for maintaining nutrition.
   
• There's a growing acknowledgment among healthcare providers about the pivotal role of nutrition in cancer treatment. Adequate nutrition can enhance treatment outcomes, mitigate complications, and uplift patients' quality of life.
   
• Thus, these dynamics are poised to drive the segment's growth in the foreseeable future.
   

The enteral feeding formulas market is segmented by end use into hospitals, long-term care facilities, home care settings, and nursing homes. In 2023, the hospitals segment was valued at USD 3.2 billion.
 

• There's a rising recognition in the healthcare sector about the vital role of nutrition in patient recovery and health outcomes. Enteral nutrition can expedite wound healing, minimize complications, and shorten recovery durations for hospitalized patients.
   
• Growing awareness about malnutrition in hospitals is spurring the demand for enteral feeding. With screening protocols in place to identify at-risk patients, hospitals are increasingly turning to enteral nutrition. The National Institutes of Health notes that malnutrition impacts 20% to 50% of hospitalized patients globally, underscoring the need for robust nutritional support.
   
• Health organizations and regulatory entities are underscoring the significance of nutritional support in clinical settings. Guidelines advocating for enteral nutrition in certain patient groups are prompting hospitals to weave these formulas into standard care. For instance, the European Society for Clinical Nutrition and Metabolism (ESPEN) emphasizes initiating enteral nutrition within 24-48 hours for critically ill patients unable to maintain oral intake.
   
• Thus, the heightened focus on nutrition in healthcare, bolstered by insights from esteemed health organizations, is set to fuel the adoption and evolution of enteral nutrition solutions in hospitals.
   

In 2023, the U.S. enteral feeding formulas market was valued at USD 2.8 billion, with projections indicating a growth at a CAGR of 7.2% over the forecast period.
 

• The U.S. enteral feeding market boasts a robust presence of players innovating product formulations, such as lactose-free, gluten-free, and low-residue options. These innovations cater to a diverse range of patient needs and preferences, propelling market growth.
   
• The aging demographic in the U.S. plays a pivotal role in driving the demand for enteral feeding formulas. Data from the U.S. Census Bureau highlights a significant demographic shift: the population aged 65 and older is set to nearly double from 52 million in 2018 to an estimated 95 million by 2060. Given that older adults often grapple with health issues hindering their ability to consume food orally, enteral nutrition becomes a crucial alternative. This demographic trend is poised to sustain long-term growth in the enteral feeding market.
   
• Consequently, these factors are anticipated to propel market growth in the U.S. in the coming years.
   

From 2024 to 2032, the UK enteral feeding formulas market is poised for notable expansion.
 

• The National Health Service (NHS) in the UK has heightened its emphasis on nutritional care as a vital element of patient management. For example, the British Dietetic Association's 'Nutrition and Hydration Digest' offers in-depth guidance for healthcare professionals. Such initiatives have led to a surge in the use of enteral feeding formulas, enhancing patient outcomes.
   
• The UK has established stringent regulatory frameworks ensuring the quality and safety of enteral feeding products. NHS England's 2022/23 operational guidance underscores the importance of nutrition and hydration in healthcare. With developed guidelines ensuring proper patient nutrition, especially in hospitals, these regulations incentivize manufacturers to produce high-quality formulas, ultimately benefiting patients reliant on enteral nutrition.
   
• Thus, heightened awareness and government initiatives are set to significantly drive market growth in the UK in the coming years.
   

Japan's enteral feeding formulas market is set for considerable growth between 2024 and 2032.
 

• Japan boasts one of the highest global life expectancies, with averages of 87.14 years for women and 81.09 years for men in 2023, as reported by the World Health Organization (WHO). This longevity has resulted in a swiftly aging populace, with 29.1% of citizens aged 65 or older in 2023, according to BBC reports. Given that older adults often face chronic health challenges and oral intake difficulties, the rising demand for enteral feeding formulas becomes evident. This demographic trend is poised to continue fueling the growth of Japan's enteral feeding market.
   
• The Japanese healthcare system prioritizes nutritional management. For instance, the Japanese Society of Intensive Care Medicine has crafted detailed guidelines for Nutrition Support Therapy for both adult and pediatric critically ill patients.
   
• There's a growing acknowledgment among healthcare providers about the pivotal role of nutrition in recovery and enhancing life quality for chronic illness patients. This understanding is driving the increasing demand for enteral feeding solutions in Japan. As the nation continues to focus on healthcare improvements, the enteral feeding market is set to expand to meet the rising nutritional demands.
   
• Given these insights, the factors highlighted are poised to bolster market growth in Japan over the forecast period.
   

Saudi Arabia's enteral feeding formulas market is on track for significant growth from 2024 to 2032.
 

• As part of its Vision 2030 initiative, the Saudi government is making substantial investments in healthcare infrastructure. This includes not only expanding hospitals and healthcare facilities but also enhancing access to enteral feeding products and services. Such efforts are expected to amplify the demand for enteral feeding products across the nation.
   
• Saudi Arabia is witnessing a surge in chronic diseases, notably diabetes, obesity, and cancer. The Saudi Ministry of Health highlights the country's diabetes prevalence as one of the highest globally, often leading to complications that require enteral nutrition support.
   
• Data from the International Diabetes Federation indicates that in 2021, 17.7% of adults in Saudi Arabia were diabetic, a figure notably above the global average. Given this high diabetes prevalence and its associated complications, the demand for enteral feeding solutions in Saudi Arabia is set to rise.
   
• In light of these insights, the factors discussed are anticipated to drive market growth in Saudi Arabia in the coming years.
   

Enteral Feeding Formulas Market Share

The market is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A key aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprints amidst evolving regulatory landscapes.

Enteral Feeding Formulas Market Companies

Some of the eminent market participants operating in the enteral feeding formulas industry include:

• Abbott Laboratories
• B. Braun Melsungen AG
• Baxter International
• Danone S.A.
• Fresenius Kabi
• Functional Formularies
• Hormel Health Labs
• Kate Farms
• Medtrition
• Meiji Holdings
• Nestlé
• NutriMedical
• Real Food Blends
• Vegenat Healthcare
• Victus
   

Enteral Feeding Formulas Industry News

• In August 2024, Abbott Laboratories announced a collaboration with the American Diabetes Association (ADA) to gain deeper insights into the nutritional needs of individuals with diabetes, obesity, and metabolic disorders. This collaboration aims to explore how specialized nutrition formulas can support both the specific dietary requirements and overall health of these individuals.
   
• In November 2021, Abbott Laboratories announced the introduction of Similac 360 Total Care, a new generation of infant formula designed to closely mimic the nutritional composition of human breast milk. This formula incorporates Human Milk Oligosaccharides (HMOs), significant prebiotics that are structurally identical to those found in breast milk.
   

The enteral feeding formulas market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Standard formulas
• Disease specific formulas
• Elemental formulas
• Semi-elemental formulas
• Other formulas

Market, By Stage

• Adults
• Pediatric

Market, By Application

• Oncology
• Gastrointestinal diseases
• Neurological disorders
• Diabetes
• Critical care
• Other applications

Market, By End Use

• Hospitals
• Long term care facilities
• Home care settings
• Nursing homes

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE